Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas (TENEC)
NCT04122911Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in neuroendocrine carcinoma (NEC), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 6 months. Started Jan 2017; status: completed.
02
Drugs
temozolomide
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT04122911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04122911.